<DOC>
	<DOC>NCT02090153</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and safety of S-1 plus Leucovorin (1 week on and 1 week off) as first-line treatment for patients with metastatic and recurrent gastric cancer.</brief_summary>
	<brief_title>Study of S-1 Plus LV for Advanced Gastric Cancer</brief_title>
	<detailed_description>Patients enrolled in this study were orally treated with S-1 in doses of 40 mg (body surface area (BSA)&lt;1.25 m2), 50 mg (1.25≤BSA&lt;1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks. Treatment was continued until progressive disease (PD), unacceptable toxicity or patient refusal.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>histologically conﬁrmed metastatic or recurrent gastric cancer with at least one measurable lesion by RECIST criteria an age of ≥ 18 adequate oral intake no previous radiotherapy, immunotherapy, biotherapy, hormonotherapy and chemotherapy within 5 years (adjuvant chemotherapy without S1 was allowed if ﬁnished 6 months before enrollment) an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 adequate bone marrow function, hepatic function and renal functions a history of hypersensitivity to S1 or LV, usage of drugs interacting with S1 serious concomitant conditions (severe heart disease, pulmonary ﬁbrosis, intestinal obstruction, enteroplegia, renal failure, liver failure, preexisting sensory neuropathy ≥ grade 2, uncontrolled infections, psychogenic disorders, human immunodeﬁciency virus infection, severe diarrhea, nausea, or vomiting, severe ascites or pleural effusion, etc.) extensive bone metastasis, brain metastasis or meningeal metastasis another synchronous cancer surgery within 3 weeks before enrollment participating in other clinical studies women who were or to be pregnant, nursing infants, and men who were to conceive children</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Advance Gastric Cancer,</keyword>
	<keyword>S-1 plus leucovorin,</keyword>
	<keyword>ORR,</keyword>
	<keyword>OS,</keyword>
	<keyword>TTP,</keyword>
	<keyword>TTF,</keyword>
	<keyword>Adverse events,</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>